TY - JOUR
T1 - MLL2 Mutation Spectrum in 45 Patients with Kabuki Syndrome
AU - Paulussen, Aimee D. C.
AU - Stegmann, Alexander P. A.
AU - Blok, Marinus J.
AU - Tserpelis, Demis
AU - Posma-Velter, Crool
AU - Detisch, Yvonne
AU - Smeets, Eric E. J. G. L.
AU - Wagemans, Annemieke M. A.
AU - Schrander, Jaap J. P.
AU - van den Boogaard, Marie Jose H.
AU - van der Smagt, Jasper J.
AU - van Haeringen, Arie
AU - Stolte-Dijkstra, Irene
AU - Kerstjens-Frederikse, Wilhelmina S.
AU - Mancini, Grazia M. S.
AU - Wessels, Marja W.
AU - Hennekam, Raoul C. M.
AU - Vreeburg, Maaike
AU - Geraedts, Joep
AU - de Ravel, Thomy
AU - Fryns, Jean-Pierre
AU - Smeets, Hubert J T
AU - Devriendt, Koenraad
AU - Schrander-Stumpel, Constance T. R. M.
PY - 2011/2
Y1 - 2011/2
N2 - Kabuki Syndrome (KS) is a rare syndrome characterized by intellectual disability and multiple congenital abnormalities, in particular a distinct dysmorphic facial appearance. KS is caused by mutations in the MLL2 gene, encoding an H3K4 histone methyl transferase which acts as an epigenetic transcriptional activator during growth and development. Direct sequencing of all 54 exons of the MLL2 gene in 45 clinically well-defined KS patients identified 34 (75.6%) different mutations. One mutation has been described previously, all others are novel. Clinically, all KS patients were sporadic, and mutations were de novo for all 27 families for which both parents were available. We detected nonsense (n=11), frameshift (n=17), splice site (n=4) and missense (n=2) mutations, predicting a high frequency of absent or non-functional MLL2 protein. Interestingly, both missense mutations located in the C-terminal conserved functional domains of the protein. Phenotypically our study indicated a statistically significant difference in the presence of a distinct facial appearance (p=0.0143) and growth retardation (p=0.0040) when comparing KS patients with an MLL2 mutation compared to patients without a mutation. Our data double the number of MLL2 mutations in KS reported so far and widen the spectrum of MLL2 mutations and disease mechanisms in KS.
AB - Kabuki Syndrome (KS) is a rare syndrome characterized by intellectual disability and multiple congenital abnormalities, in particular a distinct dysmorphic facial appearance. KS is caused by mutations in the MLL2 gene, encoding an H3K4 histone methyl transferase which acts as an epigenetic transcriptional activator during growth and development. Direct sequencing of all 54 exons of the MLL2 gene in 45 clinically well-defined KS patients identified 34 (75.6%) different mutations. One mutation has been described previously, all others are novel. Clinically, all KS patients were sporadic, and mutations were de novo for all 27 families for which both parents were available. We detected nonsense (n=11), frameshift (n=17), splice site (n=4) and missense (n=2) mutations, predicting a high frequency of absent or non-functional MLL2 protein. Interestingly, both missense mutations located in the C-terminal conserved functional domains of the protein. Phenotypically our study indicated a statistically significant difference in the presence of a distinct facial appearance (p=0.0143) and growth retardation (p=0.0040) when comparing KS patients with an MLL2 mutation compared to patients without a mutation. Our data double the number of MLL2 mutations in KS reported so far and widen the spectrum of MLL2 mutations and disease mechanisms in KS.
KW - Kabuki syndrome
KW - KS
KW - MLL2
KW - histone methyl transferase
U2 - 10.1002/humu.21416
DO - 10.1002/humu.21416
M3 - Article
C2 - 21280141
SN - 1059-7794
VL - 32
SP - E2018-E2025
JO - Human Mutation
JF - Human Mutation
IS - 2
ER -